$ACTU
ACTUATE THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000168316824007971 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.636M
YoY Change
% of Gross Profit
Research & Development $3.757M $5.762M
YoY Change -34.79%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.393M $6.476M
YoY Change -16.72%
Operating Profit -$5.393M -$6.476M
YoY Change -16.72%
Interest Expense -$1.115M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$578.1K $137.7K
YoY Change -519.65%
Pretax Income -$5.971M
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$5.971M -$6.338M
YoY Change -5.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55 -$4.31
Diluted Earnings Per Share -$0.55 -$4.31
COMMON SHARES
Basic Shares Outstanding 19.53M shares 19.53M shares 1.472M shares
Diluted Shares Outstanding 10.77M shares 1.472M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.52M
YoY Change
Cash & Equivalents $13.52M $8.471M
Short-Term Investments
Other Short-Term Assets $739.3K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.26M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $14.26M
Total Long-Term Assets $0.00
Total Assets $14.26M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.330M
YoY Change
Accrued Expenses $6.167M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.497M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $405.0K
YoY Change
Other Long-Term Liabilities $1.690K
YoY Change
Total Long-Term Liabilities $406.7K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $8.497M
Total Long-Term Liabilities $406.7K
Total Liabilities $8.904M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$125.9M
YoY Change
Common Stock $20.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.359M -$92.14M
YoY Change
Total Liabilities & Shareholders Equity $14.26M
YoY Change

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.971M -$6.338M
YoY Change -5.79%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$9.149M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 22.32M
YoY Change
NET CHANGE
Cash From Operating Activities -9.149M
Cash From Investing Activities
Cash From Financing Activities 22.32M
Net Change In Cash 13.17M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$9.149M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001652935
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19531636 shares
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13523449 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2958659 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
36907 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
14262781 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2995566 usd
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
0 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
277500 usd
CY2024Q3 us-gaap Interest Payable Current
InterestPayableCurrent
70957 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0 usd
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33463018 shares
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
usd
CY2023Q2 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-42139
dei Entity Registrant Name
EntityRegistrantName
Actuate Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3044785
dei Entity Address Address Line1
EntityAddressAddressLine1
1751 River Run
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Worth
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
76107
dei City Area Code
CityAreaCode
817
dei Local Phone Number
LocalPhoneNumber
887-8455
dei Security12b Title
Security12bTitle
Common Stock, par value $0.000001 per share
dei Trading Symbol
TradingSymbol
ACTU
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
739332 usd
CY2024Q3 us-gaap Assets
Assets
14262781 usd
CY2023Q4 us-gaap Assets
Assets
2995566 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2330005 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3421840 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6096448 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3221254 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8497410 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6920594 usd
CY2024Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
0 usd
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
988049 usd
CY2024Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1692 usd
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
130041 usd
CY2024Q3 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
404991 usd
CY2023Q4 us-gaap Accounts Payable Other Current And Noncurrent
AccountsPayableOtherCurrentAndNoncurrent
404991 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
406683 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1523081 usd
CY2024Q3 us-gaap Liabilities
Liabilities
8904093 usd
CY2023Q4 us-gaap Liabilities
Liabilities
8443675 usd
CY2024Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.000001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2024Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
24678355 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
24678355 shares
CY2024Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0 usd
CY2023Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
121033336 usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
94178404 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19531636 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19531636 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
38108584 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1690760 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1690760 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
20 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131292428 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5468006 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125933760 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105094521 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5358688 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99626513 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14262781 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2995566 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3757102 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5761506 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14990337 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15062505 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1635801 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
714167 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3611269 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2296143 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
5392903 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6475673 usd
us-gaap Operating Expenses
OperatingExpenses
18601606 usd
us-gaap Operating Expenses
OperatingExpenses
17358648 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5392903 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6475673 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-18601606 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17358648 usd
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-193951 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16866 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
78903 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
28224 usd
CY2024Q3 ACTU Gain On Settlement Of Warrants
GainOnSettlementOfWarrants
343240 usd
CY2023Q3 ACTU Gain On Settlement Of Warrants
GainOnSettlementOfWarrants
0 usd
ACTU Gain On Settlement Of Warrants
GainOnSettlementOfWarrants
343240 usd
ACTU Gain On Settlement Of Warrants
GainOnSettlementOfWarrants
0 usd
CY2024Q3 ACTU Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value
LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue
-0 usd
CY2023Q3 ACTU Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value
LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue
-0 usd
ACTU Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value
LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue
400000 usd
ACTU Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value
LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue
-0 usd
CY2024Q3 ACTU Change In Estimated Fair Value Of Related Party Convertible Notes Payable
ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable
1192507 usd
CY2023Q3 ACTU Change In Estimated Fair Value Of Related Party Convertible Notes Payable
ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable
-0 usd
ACTU Change In Estimated Fair Value Of Related Party Convertible Notes Payable
ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable
2192507 usd
ACTU Change In Estimated Fair Value Of Related Party Convertible Notes Payable
ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable
-0 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3489 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5062 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
13641 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
38578 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
80747 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
125944 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
104178 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
292984 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-578058 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
137748 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2237633 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
226182 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5970961 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6337925 usd
us-gaap Net Income Loss
NetIncomeLoss
-20839239 usd
us-gaap Net Income Loss
NetIncomeLoss
-17132466 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10772640 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10772640 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1472182 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1472182 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4647199 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4647199 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1412151 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1412151 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.13
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-99626513 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
148206 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8296059 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-107774366 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
90019 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6572219 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-114256566 usd
CY2024Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3734389 usd
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
22025611 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
94178404 usd
CY2024Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
8092507 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
485172 usd
CY2024Q3 ACTU Stock Issued During Period Value Warrants To Purchase Redeemable Convertible Stock
StockIssuedDuringPeriodValueWarrantsToPurchaseRedeemableConvertibleStock
238540 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
565981 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5970961 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
5358688 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-75305432 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
73131 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
206821 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5270255 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-80502556 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
73131 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
114679 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5524286 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-85953711 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
155227 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6337925 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-92136409 usd
us-gaap Net Income Loss
NetIncomeLoss
-20839239 usd
us-gaap Net Income Loss
NetIncomeLoss
-17132466 usd
us-gaap Share Based Compensation
ShareBasedCompensation
804206 usd
us-gaap Share Based Compensation
ShareBasedCompensation
301489 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
78903 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
28224 usd
ACTU Gain On Settlement Of Warrant Liability
GainOnSettlementOfWarrantLiability
343240 usd
ACTU Gain On Settlement Of Warrant Liability
GainOnSettlementOfWarrantLiability
-0 usd
ACTU Loss On Issuance Of Related Party Convertible Note Payable At Fair Value
LossOnIssuanceOfRelatedPartyConvertibleNotePayableAtFairValue
400000 usd
ACTU Loss On Issuance Of Related Party Convertible Note Payable At Fair Value
LossOnIssuanceOfRelatedPartyConvertibleNotePayableAtFairValue
0 usd
ACTU Change In Estimated Fair Value Of Related Party Convertible Note Payable
ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotePayable
2192507 usd
ACTU Change In Estimated Fair Value Of Related Party Convertible Note Payable
ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotePayable
0 usd
ACTU Interest Accrued On License Payable
InterestAccruedOnLicensePayable
13565 usd
ACTU Interest Accrued On License Payable
InterestAccruedOnLicensePayable
38579 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
702425 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-3806 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1197747 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
426310 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-277500 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-132033 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-70957 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2871694 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
352768 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17070233 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16113323 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
23956800 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
1821777 usd
us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
-0 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
200000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
200000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5500000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
4134516 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27635023 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4134516 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
10564790 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11978807 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2958659 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20449310 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13523449 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8470503 usd
us-gaap Interest Paid Net
InterestPaidNet
71033 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
800 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
ACTU Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
94178404 usd
ACTU Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Initial Public Offering
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponInitialPublicOffering
0 usd
ACTU Reclassification Of Warrant Liability To Equity Upon Exchange Of Not Inthemoney Series B And Series C Redeemable Convertible Preferred Stock Warrants For Warrants To Purchase Common Stock
ReclassificationOfWarrantLiabilityToEquityUponExchangeOfNotInthemoneySeriesBAndSeriesCRedeemableConvertiblePreferredStockWarrantsForWarrantsToPurchaseCommonStock
485172 usd
ACTU Reclassification Of Warrant Liability To Equity Upon Exchange Of Not Inthemoney Series B And Series C Redeemable Convertible Preferred Stock Warrants For Warrants To Purchase Common Stock
ReclassificationOfWarrantLiabilityToEquityUponExchangeOfNotInthemoneySeriesBAndSeriesCRedeemableConvertiblePreferredStockWarrantsForWarrantsToPurchaseCommonStock
0 usd
ACTU Settlement Of Inthemoney Warrants To Purchase Redeemable Convertible Preferred Stock And Conversion Into Common Stock Upon Initial Public Offering
SettlementOfInthemoneyWarrantsToPurchaseRedeemableConvertiblePreferredStockAndConversionIntoCommonStockUponInitialPublicOffering
238540 usd
ACTU Settlement Of Inthemoney Warrants To Purchase Redeemable Convertible Preferred Stock And Conversion Into Common Stock Upon Initial Public Offering
SettlementOfInthemoneyWarrantsToPurchaseRedeemableConvertiblePreferredStockAndConversionIntoCommonStockUponInitialPublicOffering
0 usd
ACTU Conversion Of Related Party Convertible Notes Payable Into Common Stock Upon Initial Public Offering
ConversionOfRelatedPartyConvertibleNotesPayableIntoCommonStockUponInitialPublicOffering
8092507 usd
ACTU Conversion Of Related Party Convertible Notes Payable Into Common Stock Upon Initial Public Offering
ConversionOfRelatedPartyConvertibleNotesPayableIntoCommonStockUponInitialPublicOffering
0 usd
ACTU Accrued And Unpaid Offering Costs
AccruedAndUnpaidOfferingCosts
109412 usd
ACTU Accrued And Unpaid Offering Costs
AccruedAndUnpaidOfferingCosts
0 usd
ACTU Estimated Fair Market Value Of Warrants Issued To Placement Agent In Connection With Issuance Of Redeemable Convertible Preferred Stock
EstimatedFairMarketValueOfWarrantsIssuedToPlacementAgentInConnectionWithIssuanceOfRedeemableConvertiblePreferredStock
0 usd
ACTU Estimated Fair Market Value Of Warrants Issued To Placement Agent In Connection With Issuance Of Redeemable Convertible Preferred Stock
EstimatedFairMarketValueOfWarrantsIssuedToPlacementAgentInConnectionWithIssuanceOfRedeemableConvertiblePreferredStock
93863 usd
CY2024Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-1.8 reverse stock split
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13523449 usd
CY2024Q3 ACTU Working Capital
WorkingCapital
-5765371 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84F_eus-gaap--UseOfEstimates_zDrL513Ns29e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86A_zidWfT8ixRy1">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets, liabilities, expenses, and related disclosures in the accompanying notes. The Company bases its estimates, assumptions and judgements on historical experience when available and on various factors that it believes to be reasonable under the circumstances as of the date of the accompanying unaudited condensed consolidated financial statements including the fair value of its common stock, fair value of the warrant liability, fair value of Related Party Convertible Notes Payable, stock-based compensation expense, accrued expenses (including accrued expenses related to research and development (“R&amp;D”) as described below), and the recoverability of the Company’s net deferred tax assets and related valuation allowance. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying unaudited condensed consolidated financial statements under different assumptions or conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0 usd
ACTU Related Party Convertibles Notes Payable
RelatedPartyConvertiblesNotesPayable
400000 usd
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
6096448 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3221254 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
0 usd
ACTU Principal Amount Of Related Party Convertible Notes Payable Issued
PrincipalAmountOfRelatedPartyConvertibleNotesPayableIssued
5500000 usd
ACTU Loss On Issuance Of Related Party Convertible Notes Payable At Fair Value
LossOnIssuanceOfRelatedPartyConvertibleNotesPayableAtFairValue
400000 usd
ACTU Change In Estimated Fair Value Of Related Party Convertible Notes Payable
ChangeInEstimatedFairValueOfRelatedPartyConvertibleNotesPayable
2192507 usd
ACTU Conversion Into Common Stock Related Party Convertible Notes Payable At Fair Value
ConversionIntoCommonStockRelatedPartyConvertibleNotesPayableAtFairValue
-8092507 usd
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19531636 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19531636 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1690760 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1690760 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
38108584 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33463018 shares
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.000001
CY2024Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33463018 shares
CY2024Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
24678355 shares
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
24678355 shares
CY2024Q3 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
96715222 usd
CY2024Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
13710379 shares
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33463018 shares
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
24678355 shares
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
24678355 shares
CY2023Q4 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
96715222 usd
CY2023Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
121033336 usd
CY2023Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
13710379 shares
CY2024Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 usd
CY2023Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 usd
CY2024Q3 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
0.555555 pure
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3965389 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
255599 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
255599 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
265566 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
497751 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.15
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
763317 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.41
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
565981 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
155227 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
804206 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
301489 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5970961 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6337925 usd
us-gaap Net Income Loss
NetIncomeLoss
-20839239 usd
us-gaap Net Income Loss
NetIncomeLoss
-17132466 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10772640 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10772640 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1472182 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1472182 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4647199 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4647199 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1412151 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1412151 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-12.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-12.13
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1640132 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14307368 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-007971-index-headers.html Edgar Link pending
0001683168-24-007971-index.html Edgar Link pending
0001683168-24-007971.txt Edgar Link pending
0001683168-24-007971-xbrl.zip Edgar Link pending
actu-20240930.xsd Edgar Link pending
actuate_ex3101.htm Edgar Link pending
actuate_ex3102.htm Edgar Link pending
actuate_ex3201.htm Edgar Link pending
actuate_i10q-093024.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
actu-20240930_def.xml Edgar Link unprocessable
actu-20240930_lab.xml Edgar Link unprocessable
actu-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
actuate_i10q-093024_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
actu-20240930_cal.xml Edgar Link unprocessable